Receive artist-designed, limited-edition covers with your print subscription Enjoy 12 digital issues a year from the global ...

French biotechnology company MaaT Pharma has reported positive results from an interim safety analysis of its Phase IIb PHOEBUS trial of MaaT033 in subjects undergoing allogeneic haematopoietic ...